Efficacy and Safety of Nemolizumab for Treatment of Adult Atopic Dermatitis: A Meta-analysis of Randomized Clinical Trials

Xiao X1,*, Lin L1,*, Zhu C1, Yang X1, Ni Y1, Zhipeng L1, Chong F, Han Y1

1Department of Dermatology, the Union Hospital, Fujian Medical University, Fuzhou, P.R. China
2College of Materials Science and Engineering, Nanjing Forestry University, Nanjing, P.R. China
*These authors contributed to the work equally.

J Investig Allergol Clin Immunol 2021; Vol. 31(2): 190-192
doi: 10.18176/jiaci.0672

Key words: Nemolizumab. Meta-analysis. Atopic dermatitis. Efficacy. Safety.

Palabras clave: Nemolizumab. Meta análisis. Dermatitis atópica. Eficacia. Seguridad.

To the Editor:

Nemolizumab is a recently developed human monoclonal antibody targeting the interleukin-31 receptor (IL-31R) [1-3]. In this meta-analysis, we aimed to explore the efficacy and safety of nemolizumab for the treatment of atopic dermatitis (AD).

On October 15, 2020, we conducted a systematic search of the Embase, Medline, PubMed, and Web of Science databases for randomized controlled trials (RCTs) using the search terms “nemolizumab” and “atopic dermatitis” or “eczema”. A total of 4 randomized, double-blinded, and placebo-controlled clinical trials (1 phase 1 trial, 2 phase 2 trials, and 1 phase 3 trial) were included in our meta-analysis of 729 patients diagnosed with moderate-to-severe AD (Supplementary Figure 1) [4-7]. In the phase 1 trial, the doses administered were 0.3, 1.0, and 3.0 mg/kg. The 2 later phase 2 trials were independent trials with an identical clinical design that were performed to evaluate the consistency of the safety and efficacy profiles of nemolizumab, where patients received nemolizumab 0.1 mg/kg once every 4 weeks (q4w), 0.5 mg/kg q4w, 2.0 mg/kg q4w, 2.0 mg/kg q8w, 10 mg q4w, 30 mg q4w, and 90 mg q4w. In the phase 3 trial, the treatment group received a 60-mg dose of nemolizumab (Supplementary Table 1). All patients were adults, had Eczema Area and Severity Index (EASI) scores >10 or SCORAD scores >25, and a >1-year history of AD. All studies included in the systematic review exhibited a low risk of bias according to the Cochrane collaboration tool, and funnel plot and Egger test analyses revealed no significant publication bias (Supplementary Figure 2). Furthermore, the quality of each RCT was estimated using the Jadad scale, and all 4 RCTs were found to be of high quality (Supplementary Table 2).

A pooled analysis of all 4 RCTs indicated that treatment with nemolizumab resulted in significant improvements in efficacy and safety based on various clinical indices.
As shown in the Figure, treatment with nemolizumab led to significantly decreased EASI scores compared with the placebo group (standardized mean difference [SMD], −0.31; 95% CI, −0.45 to −0.17; \( P < .001 \)). A meta-analysis of the 2 phase 2 RCTs suggested a significant reduction in the SCORAD score in the nemolizumab group compared with the placebo group (SMD, −0.56; 95% CI, −1.05 to −0.07; \( P = .025 \)). A reduction in the VAS for pruritus indicates relief for patients and a significant improvement in quality of life. In the pooled nemolizumab group, the SMD of the VAS for pruritus was −3.95 (95% CI, −5.56 to −2.37; \( P < .001 \)). The results showed a significant decrease in the SMD body surface area score in the nemolizumab group compared with the control group (SMD, −0.19; 95% CI, −0.35 to −0.03; \( P = .019 \)). There was a significant difference in the percentage of IgA response in the nemolizumab treatment group compared with the placebo group (RR, 0.81; 95% CI, −0.65 to −1.01; \( P = .064 \)). In addition to the overall efficacy of nemolizumab, dose-dependent efficacy was also investigated in this systematic review. Doses of 60 mg q4w,
3.0 mg/kg q4w, and 2.0 mg/kg q4w resulted in the most effective clinical improvement, while doses of 30 mg q4w and 90 mg q4w were less effective but led to significant improvements. Doses of 0.1 mg/kg q4w, 0.5 mg/kg q4w, and 10 mg q4w resulted in barely significant improvements. A Galbraith radial plot confirmed that nemolizumab regimens with doses of 0.1 mg/kg q4w, 0.5 mg/kg q4w, and 2.0 mg/kg q8w were not as safe as those with doses of 0.3 mg/kg q4w and 60 mg q4w (Supplementary Figure 3). Based on the efficacy and safety results, the optimal dose of nemolizumab for the treatment of patients with moderate-to-severe AD is likely to be 60 mg q4w.

Overall, the results of the RCTs included demonstrate that nemolizumab has an acceptable safety profile, as there was no significant difference in adverse events or severe adverse events compared with the placebo group. The adverse event rate did not differ significantly among the 4 trials (RR, 0.84; 95%CI, 0.69-1.01; \( P = 0.069 \)). Furthermore, the severe adverse event rate did not differ significantly between the placebo control and nemolizumab groups (RR, 1.27; 95%CI, 0.97-1.66; \( P = 0.079 \)) (Supplementary Figure 4).

Our findings clearly demonstrate that nemolizumab is a promising anti-AD medication and provide evidence that it can be used to treat AD efficiently and specifically. Further studies should be conducted to assess the long-term stability, efficacy, and safety of nemolizumab for treatment of AD.

Acknowledgments

All the research work was conducted at the Department of Dermatology, Union Hospital Affiliated Fujian Medical University. We would like to thank Xu Yao for help processing the results.

Funding

National Natural Science Foundation of China (81602785), Fujian Province Natural Science Foundation (2017J05128), Fujian Provincial Health Technology Project (2019-ZQN-47), and the Opening Foundation of Research Platform of Fujian University of Traditional Chinese Medicine (X2018018-Platform).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

1. Bağci IS, Ruzicka T. IL-31: A new key player in dermatology and beyond. J Allergy Clin Immunol. 2018;141(3):858-66.
2. Furue M, Yamamura K, Kido-Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29-36.
3. Ruzicka T, Hanifin JM, Furue M, Pulka G, Mlynarczyk I, Wollenberg A, et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. N Engl J Med. 2017;376(9):826-35.
4. Nemoto O, Furue M, Nakagawa H, Shiramoto M, Hanada R, Matsuki S, et al. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study. Br J Dermatol. 2016;174(2):296-04.
5. Kabashima K, Furue M, Hanifin JM, Pulka G, Wollenberg A, Galus R, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142(4):1121-30.e7.
6. Silverberg JI, Pinter A, Pulka G, Poulin Y, Bouaziz JD, Wollenberg A, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-82.
7. Kabashima K, Matsumura T, Komazaki H, Kawashima M; Nemolizumab-JP01 Study Group. Nemolizumab-JP01 Study Group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383(2):141-50.

Manuscript received January 11, 2021; accepted for publication January 20, 2021.

Yue Han

Xinquan Road 29
Fuzhou 350001
People’s Republic of China.
E-mail: dr_hanyue@126.com

© 2021 Esmon Publicidad J Investig Allergol Clin Immunol 2021; Vol. 31(2): 182-195